en · de · es · pt
thymosin-alpha-1-notes.peptides1004.com › Topic › Storage, Handling And Analytical Verification — Reference Sheet

Storage, Handling And Analytical Verification — Reference Sheet

By Editorial Desk · published 2026-05-02 · last reviewed 2026-06-14 · Topic

Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-06-14. Numbers and descriptions here follow the published literature rather than marketing material.

Storage, Handling and Analytical Verification

Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.

Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.

Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.

Background and Molecular Profile

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

Thymosin-alpha-1 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderHygroscopic; let the vial equilibrate before opening
SolubilityFreely soluble in water and aqueous buffersWorking solutions are often prepared between 0.1 and 1 mg per mL
Typical storage temperatureAt or below 20 degrees below zero CelsiusDesiccant and sealed vials reduce moisture uptake
Routine purity assayReversed-phase HPLC with ultraviolet detectionResult reported as percentage of total peak area
Identity checkMass spectrometry with amino acid analysisObserved mass is compared with the calculated value

免疫调节机制与信号

在信号层面,Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示,它能激活髓样分化因子88依赖的通路,进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答,有助于细胞免疫。然而,具体受体和结合位点尚未完全确定,不同实验模型的结果存在差异。

临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善,但临床终点获益在不同研究中并不一致。系统综述指出,研究间在人群、剂量和联合方案上差异较大,难以汇总结论。因此,Tα1的确切临床地位仍属开放问题,需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。

胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明,它可促进未成熟T细胞向成熟T细胞分化,并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子,从而更有效地呈递抗原。此外,自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体,而是调节宿主免疫应答的强度与方向。

Related pages on this site

Molecular Identity Of Thymosin Alpha-1

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Analytical Methods and Storage Stability

The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.

Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.

Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.

Molecular Background and Immune Action

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Notes from published material

Following a hearing at the High Court, Mr Justice Linden rules that the nurses' strike planned for 30 April – 2 May is partially unlawful as it falls partly outside the six-month period from when members of the Royal College of Nursing voted to strike. The strike is cut short by a day as a consequence. The NHS COVID-19 contact tracing app closes down. 28 April – Richard Sharp resigns as chairman of the BBC over his breach of the BBC's rules regarding public appointments after failing to declare his connection to a loan secured by former prime minister Boris Johnson worth £800,000. 29 April Coronation of Charles III and Camilla: Organisers announce that among the changes to the ceremony for the coronation will be to invite people watching proceedings to swear allegiance to the King and his heirs. The service will also include female clergy and representatives from several different religions. The Guardian apologises following the publication of a cartoon depicting former BBC chairman Richard Sharp, who is Jewish, with exaggerated features and carrying a puppet of Rishi Sunak, after it was criticised for being antisemitic. The final UK rescue flight from the Sudanese capital of Khartoum takes off as the rescue of UK nationals comes to an end. Another flight from Port Sudan is subsequently arranged for 1 May. 30 April Eight people are stabbed, one fatally, in a street brawl near a nightclub in Bodmin, Cornwall. Police arrest a 24-year-old man on suspicion of murdering another man in his 30s. The deceased victim is subsequently named as Michael Allen, aged 32.

Formylglycine-generating enzyme (FGE), located at 3p26.1 in humans, is the name for an enzyme present in the endoplasmic reticulum that catalyzes the conversion of cysteine to formylglycine (fGly). There are two main classes of FGE, aerobic and anaerobic. FGE activates sulfatases, which are essential for the degradation of sulfate esters. The catalytic activity of sulfatases is dependent upon a formylglycine (sometimes called oxoalanine) residue in the active site.

Kerry-Lynne Donna Findlay (born January 12, 1955) is a Canadian politician and lawyer who served as leader of the Conservative Party of British Columbia from May to September 2026. She had served as a member of Parliament (MP) for South Surrey—White Rock from 2019 to 2025 and Delta—Richmond East from 2011 to 2015 with the federal Conservative Party. Findlay was Associate Minister of National Defence in 2013, and Minister of National Revenue from 2013 to 2015 under Prime Minister Stephen Harper.

Sources: en.wikipedia.org

Further detail

== Research == Experiments using cultured cells have demonstrated that humanin has both neuroprotective as well as cytoprotective effects and experiments in rodents have found that it has protective effects in Alzheimer's disease models, Huntington's disease models and stroke models. Humanin is proposed to have myriad neuroprotective and cytoprotective effects. Studies in both cells and rodents have found that administration of humanin or humanin derivatives increases survival and/or physiological parameters in Alzheimer's disease models. In addition to Alzheimer's disease, humanin has other neuroprotective effects against models of Huntington's disease, prion disease, and stroke. Beyond the possible neuroprotective effects, humanin protects against oxidative stress, atherosclerotic plaque formation, and heart attack. Humanin activates chaperone-mediated autophagy in a dose-dependent manner. Humanin decreases production of inflammatory cytokines, which is part of its anti-apoptotic effect. Metabolic effects have also been demonstrated and humanin helps improve survival of pancreatic beta-cells, which may help with type 1 diabetes, and increases insulin sensitivity, which may help with type 2 diabetes. In rats, the humanin analog appears to normalize glucose levels and reduce diabetes symptoms. Rattin shows the same ability as humanin to defend neurons from the toxicity of beta-amyloid, associated with the degeneration in Alzheimer's disease.

== History == Eflornithine was initially developed for cancer treatment at Merrell Dow Research Institute in the late 1970s, but was found to be ineffective in treating malignancies. However, it was discovered to be highly effective in reducing hair growth, as well as in the treatment of African trypanosomiasis (sleeping sickness), especially the West African form (Trypanosoma brucei gambiense).

=== Formation === Cold Cave was founded in 2007 by Wesley Eisold, vocalist of hardcore groups American Nightmare (briefly known as Give Up the Ghost), Some Girls, and Heartworm Press founder. Cold Cave represents Eisold's first venture into instrumentation. Eisold was born with one hand which led him to electronic music.

The classic symptom of keratoconus is the perception of multiple "ghost" images, known as monocular polyopia. This effect is most clearly seen with a high contrast field, such as a point of light on a dark background. Instead of seeing just one point, a person with keratoconus sees many images of the point, spread out in a chaotic pattern. This pattern does not typically change from day to day, but over time, it often takes on new forms. People also commonly notice streaking and flaring distortion around light sources. Some even notice the images moving relative to one another in time with their heartbeat. The predominant optical aberration of the eye in keratoconus is coma. The visual distortion experienced by the person comes from two sources, one being the irregular deformation of the surface of the cornea, and the other being scarring that occurs on its exposed highpoints. These factors act to form regions on the cornea that map an image to different locations on the retina. The effect can worsen in low light conditions, as the dark-adapted pupil dilates to expose more of the irregular surface of the cornea. Significant retinal layer thickness reduction is observed in keratoconus, especially in younger patients (<30 years).

Sources: en.wikipedia.org

Frequently asked questions

How should a dissolved solution be kept?

Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.

What purity grades are available?

Research material is commonly offered at 95 percent purity or above by chromatographic area, with some suppliers listing 98 percent. Higher grades usually carry a higher price and are chosen when the assay is sensitive to trace impurities.

Which method confirms identity?

Mass spectrometry is the standard check, often paired with amino acid analysis or peptide mapping. A chromatographic retention time alone is generally considered insufficient for structural confirmation.

How does thymosin alpha 1 differ from thymosin fraction 5?

Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.

Network